Inhalation Sciences Sweden AB (ISAB) today announces that it has received an IRS (Inhalation Research Services) order valued at approximately EUR 117,000 (approximately SEK 1.3 million) from a new customer.
The customer is a European-based pharmaceutical and biotechnology company with extensive experience in producing both generic and innovative medicines.
ISAB will use its PreciseInhale® platform technology to generate high-quality preclinical study data. The study will involve in vivo testing - meaning the research is conducted in living organisms - to evaluate how the inhaled compound behaves under real biological conditions.
"We are pleased that such a leading pharmaceutical company has chosen to partner with us for this important inhalation study. This order reflects the growing confidence in our ability to support complex preclinical inhalation research, including in vivo studies where understanding the biological response to inhaled compounds is critical", says Manoush Masarrat, CEO of Inhalation Sciences.
This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on May 18, 2026, at 10:10.
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.